Merck provides Mobius bioreactors to BioInvent International

Merck has agreed to provide a number of Mobius single-use bioreactors to the Swedish pharmaceutical company BioInvent International.

The firm, which develops novel immunoregulatory antibodies to treat cancer, is looking to upgrade and expand its drug manufacturing facility with a full line of Merck's Mobius single-use bioreactors.

A range of three, 50, 200 and 1,000-litre bioreactors will be installed at BioInvent's upstream facility in Lund, expanding its capacity and improving flexibility and scalability, while reducing the need for retraining of operators during the scale-up process.

The use of Merck's technology will allow BioInvent to meet production requirements for both its own novel antibody development projects and also those of its various international customers.

Udit Batra, member of the Merck executive board and chief executive officer of the life science business sector of Merck, said: "We are providing a full range of bioreactors, services and support, which will help BioInvent accelerate innovative therapeutics through the development pipeline."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.